5 июн. 2018 г. · The median overall survival time was 52.1 months (95% confidence interval [CI]: 23.6-not reached). In the 90 patients who were treated with ...

For patients receiving TKI, median OS was 24.3 months. Survival was inferior in case of brain metastasis (BM) at diagnosis (5.2 months). One in five patients ...

The median age of people with ROS1-positive lung cancer was 50.5. (The median age for lung cancer, in general, is 70.) ROS1-positive lung cancer was ...

Our patients on ROS1 TKI had a median PFS and OS of 27.07 months and 48.59 months compared to 6.87 and 10.9 months on chemotherapy. And except for 1 patient, ... Abstract · Introduction · Methods · 1L treatment

3 февр. 2024 г. · Prognosis. ROS1-positive lung cancer tends to be aggressive, growing, and spreading fairly rapidly. But it does respond to targeted therapy. Symptoms · Causes · Diagnosis

Median overall survival for the ROS1-patients who did not receive crizotinib treatment (n = 9) was 36.7 months, whereas the median for the five patients ...

Median overall survival with crizotinib in ROS1-positive lung cancer was 54.8 months. •. Co-occurring TP53 aberrations constitute a subgroup with impaired ...

The research enlisted the participation of 21 patients. Median progression-free survival with crizotinib treatment was found 26.1 (95% Confidence interval ...

16 февр. 2024 г. · The median progression-free survival for this group was 9 months. A small number of people in both groups had complete responses to treatment, ...